PMC:4939752 / 38848-39158 JSONTXT

{"target":"http://pubannotation.org/docs/sourcedb/PMC/sourceid/4939752","sourcedb":"PMC","sourceid":"4939752","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4939752","text":"Y90 -Ibritumomabtiuxetan (Zevalin)Approved in US 2002 Biogen IDECPharmaceuticals CorpType ImAb Murine IgG1κ Zevalin (54 patients of Rituximab refractory FL, ORR 74%) [83,84]Zevalin vs Rituximab, randomized multicenter study (143 patients ofRelapsed or refractory FL, ORR 80 vs 56%) [84,85] High CDCLow ADCC","divisions":[{"label":"td","span":{"begin":0,"end":53}},{"label":"td","span":{"begin":55,"end":95}},{"label":"td","span":{"begin":97,"end":109}},{"label":"td","span":{"begin":111,"end":292}}],"tracks":[]}